249 related articles for article (PubMed ID: 11215754)
1. SCH 23390 enhances exogenous L-DOPA decarboxylation in nigrostriatal neurons.
Neff NH; Wemlinger TA; Hadjiconstantinou M
J Neural Transm (Vienna); 2000; 107(4):429-43. PubMed ID: 11215754
[TBL] [Abstract][Full Text] [Related]
2. The antiparkinsonian drug budipine stimulates the activity of aromatic L-amino acid decarboxylase and enhances L-DOPA-induced dopamine release in rat substantia nigra.
Biggs CS; Fisher A; Starr MS
Synapse; 1998 Nov; 30(3):309-17. PubMed ID: 9776134
[TBL] [Abstract][Full Text] [Related]
3. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Holmer HK; Keyghobadi M; Moore C; Meshul CK
Neuroscience; 2005; 136(1):333-41. PubMed ID: 16198485
[TBL] [Abstract][Full Text] [Related]
4. Aromatic L-amino acid decarboxylase activity of mouse striatum is modulated via dopamine receptors.
Hadjiconstantinou M; Wemlinger TA; Sylvia CP; Hubble JP; Neff NH
J Neurochem; 1993 Jun; 60(6):2175-80. PubMed ID: 8492125
[TBL] [Abstract][Full Text] [Related]
5. Striatal adenosine A(2A) receptor blockade increases extracellular dopamine release following l-DOPA administration in intact and dopamine-denervated rats.
Gołembiowska K; Dziubina A
Neuropharmacology; 2004 Sep; 47(3):414-26. PubMed ID: 15275831
[TBL] [Abstract][Full Text] [Related]
6. Clozapine modulates aromatic L-amino acid decarboxylase activity in mouse striatum.
Neff NH; Wemlinger TA; Duchemin AM; Hadjiconstantinou M
J Pharmacol Exp Ther; 2006 May; 317(2):480-7. PubMed ID: 16415089
[TBL] [Abstract][Full Text] [Related]
7. L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease.
King JM; Muthian G; Mackey V; Smith M; Charlton C
Life Sci; 2011 Oct; 89(17-18):638-43. PubMed ID: 21871902
[TBL] [Abstract][Full Text] [Related]
8. Nigrostriatal reduction of aromatic L-amino acid decarboxylase activity in MPTP-treated squirrel monkeys: in vivo and in vitro investigations.
Yee RE; Huang SC; Stout DB; Irwin I; Shoghi-Jadid K; Togaski DM; DeLanney LE; Langston JW; Satyamurthy N; Farahani KF; Phelps ME; Barrio JR
J Neurochem; 2000 Mar; 74(3):1147-57. PubMed ID: 10693947
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine hydroxylase, aromatic L-amino acid decarboxylase and dopamine metabolism after chronic treatment with dopaminergic drugs.
Cho S; Duchemin AM; Neff NH; Hadjiconstantinou M
Brain Res; 1999 Jun; 830(2):237-45. PubMed ID: 10366680
[TBL] [Abstract][Full Text] [Related]
10. Dual effects of L-3,4-dihydroxyphenylalanine on aromatic L-amino acid decarboxylase, dopamine release and motor stimulation in the reserpine-treated rat: evidence that behaviour is dopamine independent.
Fisher A; Biggs CS; Eradiri O; Starr MS
Neuroscience; 2000; 95(1):97-111. PubMed ID: 10619466
[TBL] [Abstract][Full Text] [Related]
11. Evidence that L-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms.
Robertson GS; Robertson HA
J Neurosci; 1989 Sep; 9(9):3326-31. PubMed ID: 2795165
[TBL] [Abstract][Full Text] [Related]
12. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
Biggs CS; Starr MS
Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
[TBL] [Abstract][Full Text] [Related]
13. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Hossain MA; Weiner N
J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
[TBL] [Abstract][Full Text] [Related]
14. Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.
Riverol M; Ordóñez C; Collantes M; DiCaudo C; Peñuelas I; Arbizu J; Marcilla I; Luquin MR
Neurobiol Dis; 2014 Feb; 62():250-9. PubMed ID: 24076099
[TBL] [Abstract][Full Text] [Related]
15. The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats.
Treseder SA; Rose S; Jenner P
Eur J Neurosci; 2001 Jan; 13(1):162-70. PubMed ID: 11135014
[TBL] [Abstract][Full Text] [Related]
16. Muscarinic antagonists in substantia nigra influence the decarboxylation of L-dopa in striatum.
Izurieta-Sánchez P; Sarre S; Ebinger G; Michotte Y
Eur J Pharmacol; 2000 Jul; 399(2-3):151-60. PubMed ID: 10884514
[TBL] [Abstract][Full Text] [Related]
17. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
St-Hilaire M; Landry E; Lévesque D; Rouillard C
Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973
[TBL] [Abstract][Full Text] [Related]
18. Enhancing aromatic L-amino acid decarboxylase activity: implications for L-DOPA treatment in Parkinson's disease.
Hadjiconstantinou M; Neff NH
CNS Neurosci Ther; 2008; 14(4):340-51. PubMed ID: 19040557
[TBL] [Abstract][Full Text] [Related]
19. Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys.
Di Monte DA; DeLanney LE; Irwin I; Royland JE; Chan P; Jakowec MW; Langston JW
Brain Res; 1996 Oct; 738(1):53-9. PubMed ID: 8949927
[TBL] [Abstract][Full Text] [Related]
20. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
